Evidence map›Paper›PMID 30870121›Full record

ReviewCirculation research2019

Perspectives on Directions and Priorities for Future Preclinical Studies in Regenerative Medicine.

Lilian Grigorian Shamagian, Rosalinda Madonna, Doris Taylor, Andreu M Climent, Felipe Prosper, Luis Bras-Rosario, Antoni Bayes-Genis, Péter Ferdinandy, Francisco Fernández-Avilés, Juan Carlos Izpisua Belmonte and 2 more

Open access · bronzeAbstract readReview
In one paragraph

Review in Circulation research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Cellular and molecular mechanisms underlying cardiovascular aging.Cellular & molecular biology letters · 2025
    Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Research progress in the cardiac lymphatic system and myocardial repair after myocardial infarction.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023
    Article
  8. Article
  9. c-kitStem cell reviews and reports · 2023
    Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Extracellular Vesicle-Based Therapeutics for Heart Repair.Nanomaterials (Basel, Switzerland) · 2021
    Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 5 countries.

Lilian Grigorian ShamagianFrom the Hospital Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spain (L.G.S., A.M.C., F.F.-A.).
Rosalinda MadonnaCenter of Aging Sciences and Translational Medicine (CESI-MeT), Institute of Cardiology, G. d'Annunzio University, Chieti, Italy (R.M.).
Doris TaylorTexas Heart Institute, Houston (D.T.).
Andreu M ClimentFrom the Hospital Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spain (L.G.S., A.M.C., F.F.-A.).
Felipe ProsperClinica Universidad de Navarra, Pamplona, Spain (F.P.).
Luis Bras-RosarioCardiology Department, Santa Maria University Hospital (CHLN), Lisbon Academic Medical Centre and Cardiovascular Centre of the University of Lisbon, Faculty of Medicine, Portugal (L.B.-R.).
Antoni Bayes-GenisCIBERCV, ISCIII, Madrid, Spain (L.G.S., A.M.C., A.B.-G., F.F.-A., V.F.).
Péter FerdinandyDepartment of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary (P.F.).
Francisco Fernández-AvilésFrom the Hospital Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spain (L.G.S., A.M.C., F.F.-A.).
Juan Carlos Izpisua BelmonteSalk Institute for Biological Studies, La Jolla (J.C.I.B.).
Valentin FusterCIBERCV, ISCIII, Madrid, Spain (L.G.S., A.M.C., A.B.-G., F.F.-A., V.F.).
Roberto BolliUniversity of Louisville (R.B.).
Centro de Investigación en Red en Enfermedades Cardiovasculares · ESInstituto de Salud Carlos III · ESClinica Universidad de Navarra · ESHospital General Universitario Gregorio Marañón · ESSalk Institute for Biological Studies · USSemmelweis University · HUThe University of Texas Health Science Center at Houston · USUniversity of Lisbon · PT

Funding

Tumor Necrosis Factor Modulation of CPCsP01HL078825 · NHLBI · UNIVERSITY OF LOUISVILLE · PI BOLLI, ROBERTO · 2005 to 2021
$37.6M
Preclinical Consortium to Facilitate Translation of Cardioprotective TherapiesU24HL094373 · NHLBI · UNIVERSITY OF LOUISVILLE · PI BOLLI, ROBERTO · 2010 to 2014
$9.6M
OXYGEN RADICALS AND CARDIAC ADAPTATIONS TO ISCHEMIAR37HL055757 · NHLBI · UNIVERSITY OF LOUISVILLE · PI BOLLI, ROBERTO · 2000 to 2009
$4.9M
University of Louisville Regional Clinical Center for the CCTRNUM1HL113530 · NHLBI · UNIVERSITY OF LOUISVILLE · PI BOLLI, ROBERTO · 2012 to 2018
$2.9M
Mechanisms of CardioprotectionR01HL070897 · NHLBI · UNIVERSITY OF LOUISVILLE · PI BOLLI, ROBERTO · 2003 to 2007
$2.8M
MOLECULAR BASIS OF PRECONDITIONINGR01HL068088 · NHLBI · UNIVERSITY OF LOUISVILLE · PI GUO, YIRU · 2001 to 2005
$2.3M
Hematopoietic Stem Cell Therapy for Myocardial RegenerationR01HL076794 · NHLBI · UNIVERSITY OF LOUISVILLE · PI BOLLI, ROBERTO · 2004 to 2007
$1.9M
COMMUNITY HEALTH PROMOTIONS PROGRAMSH75DP424252 · DP · UNIVERSITY OF LOUISVILLE · PI BOLLI, ROBERTO · 2004 to 2004
–
OXYGEN RADICALS AND CARDIAC ADAPTATIONS TO ISCHEMIAR01HL055757 · NHLBI · UNIVERSITY OF LOUISVILLE · PI BOLLI, ROBERTO · 1995 to 1999
–
NCCDPHP CDC HHS H75 DP424252NHLBI NIH HHS P01 HL078825NHLBI NIH HHS R01 HL055757NHLBI NIH HHS R01 HL068088NHLBI NIH HHS R01 HL070897NHLBI NIH HHS R01 HL076794NHLBI NIH HHS R37 HL055757NHLBI NIH HHS U24 HL094373NHLBI NIH HHS UM1 HL113530
6 · The paper itself

Abstract

The myocardium consists of numerous cell types embedded in organized layers of ECM (extracellular matrix) and requires an intricate network of blood and lymphatic vessels and nerves to provide nutrients and electrical coupling to the cells. Although much of the focus has been on cardiomyocytes, these cells make up <40% of cells within a healthy adult heart. Therefore, repairing or regenerating cardiac tissue by merely reconstituting cardiomyocytes is a simplistic and ineffective approach. In fact, when an injury occurs, cardiac tissue organization is disrupted at the level of the cells, the tissue architecture, and the coordinated interaction among the cells. Thus, reconstitution of a functional tissue must reestablish electrical and mechanical communication between cardiomyocytes and restore their surrounding environment. It is also essential to restore distinctive myocardial features, such as vascular patency and pump function. In this article, we review the current status, challenges, and future priorities in cardiac regenerative or reparative medicine. In the first part, we provide an overview of our current understanding of heart repair and comment on the main contributors and mechanisms involved in innate regeneration. A brief section is dedicated to the novel concept of rejuvenation or regeneration, which we think may impact future development in the field. The last section describes regenerative therapies, where the most advanced and disruptive strategies used for myocardial repair are discussed. Our recommendations for priority areas in studies of cardiac regeneration or repair are summarized in Tables 1 and 2 .

Indexed as

Regenerative MedicineFibroblastsHumansInflammationMyocytes, CardiacRegenerationpreclinical researchregenerationrejuvenationrepair

Identifiers

PMID30870121
PMCPMC6442739
OpenAlexW2921802289

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.